Image Place holder

Kenneth S. Zuckerman, MD

Specialty: Medical Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT

or call 1-888-MOFFITT


Dr. Zuckerman has been selected in the Woodward/White Best Doctors in America and Castle Connolly America’s Top Doctors since the early 2000s, and was selected by US News in 2012 as being among the top 1% of U.S. physicians. Dr. Zuckerman never forgets that he is not only a physician, but also a professor and teacher. He takes this role seriously, not only as the director of the fellowship training program at Moffitt and USF for Hematology and Medical Oncology subspecialty trainees, but also with a commitment to spend as long as it takes to teach all of his patients about their diseases. He takes care of 2 main categories of patients. One category is patients with myeloproliferative neoplasms. These include polycythemia vera, essential thrombocythemia, myelofibrosis, hypereosinophilic syndromes, systemic mastocytosis. The second broader category is patients with a variety of benign hematology disorders, including aplastic anemia, immune thrombocytopenic purpura, and a broad range of patients with high or low white blood cell (neutrophil) counts, high or low platelet counts, and high or low red blood cell counts.

Education & Training

Board Certification:

  • Hematology


  • Harvard Medical School and Peter Bent Brigham Hospital - Hematology


  • Ohio State University Hospital - Internal Medicine

Medical School:

  • Ohio State University Medical School - MD
Participating Trials

A Phase I/II, Multicenter, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Condition: Malignant Hematology
Intervention: BI 836858

A Phase 1 Study of KB003 in Patients with Previously Treated Chronic Myelomonocytic Leukemia (CMML)
Condition: Malignant Hematology
Intervention: KB003

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


  • Visweshwar N, Jaglal M, Sokol L, Zuckerman K. Chemotherapy-related anemia. Ann Hematol. 2017 Nov. Pubmedid: 29103107.
  • Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. 2017 Mar;129(13):1881-1883. Pubmedid: 28159734.
  • Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. Clin Lymphoma Myeloma Leuk. 2017 Aug. Pubmedid: 28869184.
  • Suleiman Y, Dalia S, Liu JJ, Bowers JW, Padron E, Lancet JE, Fulp W, Moscinski LC, Komrokji RS, Zuckerman KS, Zhang L. Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia. Leuk Res. 2016 Mar;42:52-58. Pubmedid: 26894965.
  • Hu XT, Zuckerman KS. Role of cell cycle regulatory molecules in retinoic acid- and vitamin D3-induced differentiation of acute myeloid leukaemia cells. Cell Proliferat. 2014 Jun;47(3):200-210. Pubmedid: 24646031.
  • Kiss R, Polgár T, Kirabo A, Sayyah J, Figueroa NC, List AF, Sokol L, Zuckerman KS, Gali M, Bisht KS, Sayeski PP, Keseru GM. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett. 2009 Jul;19(13):3598-3601. Pubmedid: 19447617. Pmcid: PMC2812898.
  • Montenegro DE, Franklin T, Moscinski LC, Zuckerman KS, Hu XT. TGFbeta inhibits GM-CSF-induced phosphorylation of ERK and MEK in human myeloid leukaemia cell lines via inhibition of phosphatidylinositol 3-kinase (PI3-k). Cell Proliferat. 2009 Feb;42(1):1-9. Pubmedid: 19143758. Pmcid: PMC3928791.
  • Wolvetang E, Pera M, Zuckerman K. Gap junction mediated transport of shRNA between human embryonic stem cells. Biochem Bioph Res Co. 2007 Nov;363(3):610-615. Pubmedid: 17900528.
  • Hu X, Cui D, Moscinski LC, Zhang X, Maccachero V, Zuckerman KS. TGFbeta regulates the expression and activities of G2 checkpoint kinases in human myeloid leukemia cells. Cytokine. 2007 Feb;37(2):155-162. Pubmedid: 17459720.
  • Johnson J, Moscinski L, Zuckerman K. Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 3. Acute myeloid leukemia presenting with lytic bone lesions. J Clin Oncol. 2004 Jul;22(14):2968-2970. Pubmedid: 15254066.
  • Crist T, Barr W, Linas S, Zuckerman K. Using local solutions to address a national issue: ASP's recommendations to ensure the vitality of clinical research. Am J Med. 2004;116(5):359-362. Pubmedid: 14984829.
  • Hu X, Bryington M, Fisher AB, Liang X, Zhang X, Cui D, Datta I, Zuckerman KS. Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest. J Biol Chem. 2002 May;277(19):16528-16537. Pubmedid: 11864973.
  • Hu X, Zhang X, Zhong Q, Fisher AB, Bryington M, Zuckerman KS. Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells. Oncogene. 2001 Oct;20(47):6840-6850. Pubmedid: 11687963.
  • Hu X, Janssen WE, Moscinski LZC, Bryington M, Dangsupa A, Rezai-Zadeh N, Babbin BA, Zuckerman KS. An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. Cancer Res. 2001 Aug;61(16):6290-6296. Pubmedid: 11507084.
  • Hu X, Zuckerman K. Transforming growth factor: signal transduction pathways, cell cycle mediation, and effects on hematopoiesis. J Hematother Stem Cell Res. 2001;10(1):67-74. Pubmedid: 11276360.
  • Hu X, Cress, Jr. W, Zhong Q, Zuckerman K. Transforming growth factor beta inhibits the phosphorylation of pRB at multiple serine/threonine sites and differentially regulates the formation of pRB family-E2F complexes in human myeloid leukemia cells. Biochem Bioph Res Co. 2000 Oct;276(3):930-939. Pubmedid: 11027571.
  • Hu X, Zuckerman KS. Cell cycle and transcriptional control of human myeloid leukemic cells by transforming growth factor beta. Leuk Lymphoma. 2000 Jul;38(3-4):235-246. Pubmedid: 10830731.
  • Liu RY, Fan C, Liu G, Olashaw NE, Zuckerman KS. Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-alpha -supported proliferation of leukemia and lymphoma cell lines. J Biol Chem. 2000 Jul;275(28):21086-21093. Pubmedid: 10783388.
  • Hu X, Moscinski L, Valkov N, Fisher A, Hill R, Zuckerman K. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. Cell Growth Differ. 2000 Apr;11(4):191-200. Pubmedid: 10775036.
  • Hauser R, Friedlander J, Baker M, Thomas J, Zuckerman K. Adult Chediak-Higashi parkinsonian syndrome with dystonia. Mov Disord. 2000;15(4):705-708. Pubmedid: 10928582.
  • Hu X, Tang M, Fisher A, Olashaw N, Zuckerman K. TNF-alpha-induced growth suppression of CD34+ myeloid leukemic cell lines signals through TNF receptor type I and is associated with NF-kappa B activation. J Immunol. 1999 Sep;163(6):3106-3115. Pubmedid: 10477576.
  • Liu R, Fan C, Olashaw N, Wang X, Zuckerman K. Tumor necrosis factor (TNF)-alpha-induced proliferation of human Mo7e leukemic cells occurs via activation of NF-kB transcription factor. J Biol Chem. 1999 May;274(20):13877-13885. Pubmedid: 10318796.
  • Hu X, Moscinski LC, Zuckerman KS. Transforming growth factor beta inhibits growth of more differentiated myeloid leukemia cells and retinoblastoma protein phosphorylation at serine 795. Exp Hematol. 1999 Apr;27(4):605-614. Pubmedid: 10210318.
  • Liu RY, Fan C, Garcia R, Jove R, Zuckerman KS. Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood. 1999 Apr;93(7):2369-2379. Pubmedid: 10090948.
  • Hu X, Tang M, Fisher A, Olashaw N, Zuckerman K. Tumor necrosis factors alpha (TNFalpha)-induced growth suppression of CD34+ myeloid leukemic cell lines signals through TNF receptor type I and is associated with NF-kB activation. J Immunol. 1999;165:3106-3115.
  • Hu X, Moscinski L, Hill B, Chen Q, Wu J, Fisher A, Zuckerman K. Characterization of a unique factor-independent variant derived from human factor-dependent TF-1 cells: a transformed event. Leuk Res. 1998 Sep;22(9):817-826. Pubmedid: 9716013.
  • Liu R, Fan C, Mitchell S, Chen Q, Wu J, Zuckerman K. The role of type I and type II tumor necrosis factor (TNF) receptors in the ability of TNF-alpha to transduce a proliferative signal in the human megakaryoblastic leukemic cell line mo7e. Cancer Res. 1998 May;58(10):2217-2223. Pubmedid: 9605769.
  • Zuckerman K. Hematopoietic abnormalities in patients with cancer. Cancer Control. 1998 Mar;5(2 Suppl 1):6-11. Pubmedid: 10762460.
  • Hu X, Zuckerman K. Cloning and sequencing of an alternative splicing-derived cDNA variant of the GM-CSF receptor alpha subunit, which encodes a truncated protein lacking 397 bp. Am J Hematol. 1998 Jun;58(2):145-147. Pubmedid: 9625584.
  • Hu X, Zuckerman K. Removing monolayer cells from culture dishes by incubation with EDTA in studies of cell structure receptors. Biotechniques. 1996;21(5):784-786. Pubmedid: 8922612.
  • Busque L, Gilliand D, Prchal J, Sieff C, Weinstein H, Sokol J, Belickova N, Wayne A, Zuckerman K, Sokol L, Castelberry R, Emanuel P. Clonality in juvenile chronic myelogenous leukemia. Blood. 1995 Jan;85(1):21-30. Pubmedid: 7803795.
  • Hu X, Zuckerman K. Isolation of full-length cDNA clones encoding the common (beta)-subunit of the GM-CSF, IL-3, and IL-5 receptors by RT-PCR. Focus. 1995;17(1):21-24. Pubmedid: noPMID.
  • Hu X, Zuckerman K. Isolation and expression of three mRNA alternative splicing-derived variants encoding the alpha subunit of the human GM-CSF receptor (a). Blood. 1995;86:1240-1240. Pubmedid: noPMID.
  • Hu X, Emanuel PD, Zuckerman KS. Cloning and sequencing of the cDNAs encoding two alternative splicing-derived variants of the alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor. Biochim Biophys Acta. 1994 Sep;1223(2):306-308. Pubmedid: 8086503.
  • Zuckerman K. Efficacy of intensive, high dose anthracycline-based therapy in intermediate-and high-grade non-Hodgkin's lymphomas. Semin Oncol. 1994;21:59-64.
  • Hu X, Emanuel P, Zuckerman K. Cloning and sequencing of the cDNAs encoding two alternative splicing-derived variants of the alpha-subunit of the granulocyte-macrophage colony-stimulating factor receptor. Biochem Biophys Acta. 1994;1223:306-308.
  • Castleberry R, Emanuel P, Zuckerman K, Cohn S, Strauss L, Byrd R, Homans A, Chaffee S, Nitschke R, Gualtieri R. A pilot study of 13-cis-retinoic acid in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med. 1994;331:1680-1684.
  • Zuckerman K, Case D, Gams R, Prasthofer E. Chemotherapy of intermediate and high-grade non-Hodgkin's lymphomas with an intensive high-dose epirubicin-containing regimen (EVDAC). Blood. 1993;82:3564-3573.
  • Zuckerman K. Myeloproliferative disorders. Curr Opin Hematol. 1993;1:189-194.
  • Zuckerman K. Myelodysplasia. Curr Opin Hematol. 1993;1:183-188.
  • Zuckerman K. Hematopoietic growth factors in the treatment of myelodysplastic syndromes. Biotherapy Rep. 1992;2:1-7.
  • Wagner J, Broxmeyer H, Byrd R, Zehnbauer B, Schmeckpeper B, Shah N, Griffin C, Emanuel P, Zuckerman K, Cooper S, Carow C, Bias W, Santos G. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood. 1992;79:1874-1881.
  • Zuckerman KS, LoBuglio AF, Reeves JA. Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with a high-dose doxorubicin-containing regimen. J Clin Oncol. 1990 Feb;8(2):248-256. Pubmedid: 2299368.
  • Pistoia V, Carroll AJ, Prasthofer EF, Tilden AB, Zuckerman KS, Ferrarini M, Grossi CE. Establishment of Tac-negative, interleukin-2-dependent cytotoxic cell lines from large granular lymphocytes (LGL) of patients with expanded LGL populations. J Clin Immunol. 1986 Nov;6(6):457-466. Pubmedid: 3023432.
  • Zuckerman KS, Prince CW, Rhodes RK, Ribadeneira M. Resistance of the stromal cell in murine long-term bone marrow cultures to damage by ionizing radiation. Exp Hematol. 1986 Dec;14(11):1056-1062. Pubmedid: 2430823.
  • Zuckerman KS, Rhodes RK, Goodrum DD, Patel VR, Sparks B, Wells J, Wicha MS, Mayo LA. Inhibition of collagen deposition in the extracellular matrix prevents the establishment of a stroma supportive of hematopoiesis in long-term murine bone marrow cultures. J Clin Invest. 1985 Mar;75(3):970-975. Pubmedid: 3980732. Pmcid: PMC423639.
  • Dabich L, Ensminger WD, Zuckerman KS, Wheeler RH, LoBuglio AF. High-dose adriamycin combination chemotherapy for intermediate and high-grade non-Hodgkin's lymphomas. Semin Oncol. 1985 Jun;12(2 Suppl 3):212-217. Pubmedid: 3874432.
  • Zuckerman KS, Bagby GC, McCall E, Sparks B, Wells J, Patel V, Goodrum D. A monokine stimulates production of human erythroid burst-promoting activity by endothelial cells in vitro. J Clin Invest. 1985 Feb;75(2):722-725. Pubmedid: 3973026. Pmcid: PMC423565.
  • Bricker LJ, Zuckerman KS. Serotonin uptake by progeny of murine megakaryocyte precursors (CFU-M) in vitro. Exp Hematol. 1984 Sep;12(8):672-675. Pubmedid: 6489479.
  • Strother SV, Zuckerman KS, LoBuglio AF. Colchicine therapy for refractory idiopathic thrombocytopenic purpura. Arch Intern Med. 1984 Nov;144(11):2198-2200. Pubmedid: 6541898.
  • Liepman MK, Wheeler RH, Zuckerman KS, Lobuglio AF. Combination chemotherapy of refractory lymphoma with cis-dichlorodiamineplatinum, vinblastine, and bleomycin. Cancer. 1982 Dec;50(12):2736-2739. Pubmedid: 6182981.
  • Zuckerman KS. Human erythroid burst-forming units. Growth in vitro is dependent on monocytes, but not T lymphocytes. J Clin Invest. 1981 Mar;67(3):702-709. Pubmedid: 6970752. Pmcid: PMC370620.
  • Silver BJ, Zuckerman KS. Aplastic anemia: recent advances in pathogenesis and treatment. Med Clin North Am. 1980 Jul;64(4):607-629. Pubmedid: 6995726.
  • Zuckerman KS, Sullivan R, Quesenberry PJ. Effects of actinomycin D in vivo on murine erythroid stem cells. Blood. 1978 May;51(5):957-969. Pubmedid: 638254.
  • Skarin AT, Zuckerman KS, Pitman SW, Rosenthal DS, Moloney W, Frei E, Canellos GP. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood. 1977 Dec;50(6):1039-1047. Pubmedid: 303529.
  • Zuckerman KS, Neidhart JA, Balcerzak SP, LoBuglio AF. Immunologic specificity of transfer factor. J Clin Invest. 1974 Oct;54(4):997-1000. Pubmedid: 4139171. Pmcid: PMC301641.
  • Saba H, Nawab U, Nadeem S, Cosgrove D, Moscinski L, Spiers A, Balducci L, Lyman G, Zuckerman K. 1994;624a.
  • Hu X, Zuckerman K. 1993;77a.
  • Hu X, Moscinski L, Hill B, Zuckerman K. 1996;3353.